SEEGENE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21,900 KRW | 0.00% |
|
+2.10% | -4.37% |
| 14/03 | Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 24/01 | Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases | CI |
ETFs positioned on Seegene, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 11 M€ | +1.79% | ||
| 0.10% | 2 M€ | -.--% | ||
| 0.03% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +6.71% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 34 M€ | +2.14% | - |
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.37% | 733M | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -37.00% | 391M | |
| -46.94% | 383M | |
| +13.32% | 332M |
- Stock Market
- Equities
- A096530 Stock
- Funds and ETFs Seegene, Inc.
